Roughly one person in five walks around with an elevated lipoprotein(a) — and almost none of them know, because a standard physical has never tested it. Lp(a) is the closest thing preventive cardiology has to a fate marker: set almost entirely by your genes, largely indifferent to diet and exercise, invisible on a standard lipid panel, and independently associated with heart attack, stroke, and aortic valve disease.
Here is the strange part: it’s a simple, inexpensive blood test. You generally need it once in your life. Cardiology societies in Europe already recommend exactly that — one measurement in every adult. Most Americans have simply never been offered it.
What Lp(a) actually is
Lipoprotein(a) is an LDL-like particle with an extra protein — apolipoprotein(a) — stitched to its surface. That addition makes it a triple threat: it delivers cholesterol into artery walls like LDL does, it promotes inflammation in the vessel, and its structure resembles plasminogen (a clot-dissolving protein) closely enough to interfere with the body’s clot-clearing machinery.
How much of it you make is written in the LPA gene. Your level is roughly stable from early adulthood for life — which is why a single measurement tells you so much, and why “eat better” barely moves it.
What counts as high?
Assays report Lp(a) in nmol/L (particle count — preferred) or mg/dL (mass). Approximate read:
| Lp(a) | In mg/dL | How to read it |
|---|---|---|
| < 75 nmol/L | < 30 | Common; generally not considered a risk driver |
| 75–125 nmol/L | 30–50 | Borderline; interpreted in context of everything else |
| ≥ 125 nmol/L | ≥ 50 | Elevated — the threshold ACC/AHA guidelines treat as risk-enhancing; ~20% of people land here |
| ≥ 430 nmol/L | ≥ ~180 | Very high — lifetime atherosclerotic risk in the neighborhood of familial hypercholesterolemia |
Risk rises continuously — there’s no cliff at any line — and unit conversion between mg/dL and nmol/L is approximate, which is one more reason results deserve a clinician’s read rather than a lone number in a portal.
Why it matters even if your cholesterol is “perfect”
Lp(a) risk is independent: it stacks on top of whatever your LDL-C and ApoB say. Someone with textbook cholesterol and a high Lp(a) can carry substantially elevated lifetime risk of heart attack, stroke, and calcific aortic stenosis — and pass the same predisposition to their children. Because the level is inherited, one elevated result is also a family signal: first-degree relatives have a coin-flip-adjacent chance of sharing it (cascade testing is standard practice in lipid clinics).
There are no symptoms. Like most of what drives early cardiovascular disease, elevated Lp(a) announces itself only in an event — or in a blood test taken decades sooner.
“If I can’t change it, why measure it?” — the fatalism trap
This is the objection that has kept Lp(a) untested for thirty years, and it gets the logic backwards. You measure Lp(a) because it changes what everything else means:
- It recalibrates your targets. A high Lp(a) typically makes clinicians treat the risks they can modify — ApoB/LDL-C, blood pressure, glucose, smoking — more aggressively and earlier. The immovable number changes the plan for the movable ones.
- It can explain a family story. Early heart attacks in relatives with “normal cholesterol” often stop being a mystery on the day someone finally checks Lp(a).
- It’s about to become treatable. Multiple targeted Lp(a)-lowering therapies are in late-stage clinical trials. If they succeed, tens of millions of people will need to know their number; the ones who measured early will be years ahead.
- It’s one draw, once. The information-to-effort ratio is about the best in laboratory medicine.
Terve Health measures and helps you understand Lp(a); treatment decisions belong to you and a licensed clinician.
How to get your Lp(a) tested
- Ask your doctor to add it. Any major lab runs it. It is simply absent from the default physical, and insurance coverage for screening varies.
- Order it a la carte ($25–75 typically) — workable, but a solo Lp(a) without ApoB, hs-CRP, and metabolic context around it leaves the most important question (“so what do I do?”) unanswered, and no one walks you through it.
- Measure it once, inside a complete panel a physician actually reads. Terve Health is a whole-body membership: drawn at any of 2,000+ Quest locations, ordered by a licensed clinician at our medical practice, and returned as a written plain-language review that puts your Lp(a) next to your ApoB, inflammation, and metabolic markers — the combination that actually determines what it means. And if your result is the kind that needs real medical follow-up, there’s a licensed practice behind your panel that delivers it. No “discuss with your doctor” dead end.
Frequently asked questions
How often should Lp(a) be tested? For most people, once in adulthood — the level is genetically set and stable. Retesting is mainly relevant around specific clinical situations (some medications and conditions shift it modestly) at a clinician’s discretion.
Can lifestyle changes lower Lp(a)? Not meaningfully — diet and exercise, which move most lipid markers, barely touch it. That is not a reason to skip the test; it’s the reason the rest of your panel matters more once you know. (Statins do not lower Lp(a) either; several targeted therapies are in phase 3 trials.)
Is Lp(a) the same as LDL or “small dense LDL”? No. It’s a distinct particle with its own genetics and its own independent risk contribution. A standard lipid panel — even a good one — does not include it, and LDL-C calculations don’t reveal it.
Should my family get tested if mine is high? Elevated Lp(a) runs strongly in families, and clinical guidance supports cascade testing of first-degree relatives. Bring your result to your family’s clinicians — it’s exactly the kind of finding our written review will flag and explain.
nmol/L vs mg/dL — which is right? nmol/L (particle number) is the assay guidelines prefer; many US labs still report mg/dL. Conversion is approximate. Interpretation against the reporting assay is part of the clinician review every Terve Health member gets.
Sources
- Kronenberg F, et al. Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement. European Heart Journal. 2022. (Once-in-adulthood measurement; ~20% prevalence; risk thresholds.)
- Grundy SM, et al. 2018 AHA/ACC/multisociety cholesterol guideline. Circulation. 2019. (Lp(a) ≥50 mg/dL / ≥125 nmol/L as risk-enhancing factor.)
- Tsimikas S. A test in context: lipoprotein(a). Journal of the American College of Cardiology. 2017. (Mechanisms; plasminogen homology; independence of risk.)
Terve Health measures and helps you understand your biomarkers; it does not diagnose, treat, or prevent disease. Laboratory testing performed by Quest Diagnostics®; testing is ordered and results are reviewed by licensed clinicians at an independent medical practice. Always discuss results and treatment with a licensed clinician.